Allergy/Imm Medical News about Arthritis, Rheumatoid Tocilizumab IL-6

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the age of remission?
Expert Opinion on Investigational Drugs, 10/13/09

Moots RJ et al. – IL–6 is an important driver of RA pathogenesis, mediating both articular and systemic effects of the disease. Tocilizumab, an inhibitor of the IL–6 receptor (IL–6R), is beneficial in treating RA in a variety of clinical contexts. Evidence to date supports the use of tocilizumab, as monotherapy or combination therapy, as an effective approach to the treatment of RA. Here, the authors discuss key efficacy and safety data from the recently published Phase III trials.

<< Previous
GA2LEN skin test study III: Minimum battery of test inhalent...

Next >>
Cardiovascular risk factors and ultrasound evaluation of carotid...